I cannot agree more - market always reacts adversely until they understand what happened, the knee-jerk response to ABBV approval will be a downtick for GILD. I don't agree that ABBV will get a black box label - has this supplement drug been given negative labeling before by the FDA ?
Boy did the room empty fast - knee jerk reaction, bought at 93.95 - it was a gift.
When it didn't happen Friday we should have known it was going to happen today. Institutions making a ton, bottom in at 94, fundamentals still intact and now GILD is a screaming buy
Closes today above 102
What I find irreprehensible is that ESRX in likelihood has been conspiring with Insurance companies to stockpile patients for ABBVs drug in anticipation of this announcement. The drug was approved Friday and the deal is announced ( mind you I didn't say was agreed to ) at 12:01 AM Monday morning ? I say BULL&%$#. This tactic stockpiling would be an attractive bargaining tool on behalf of ESRX that to me, smacks of collusion. By stockpiling they would also be able to bolster ABBVs prescription numbers near term and create a false sense that ABBVs drug is attracting more their anticipated prescription numbers - another sales tool.
Also what I find odd is that wasn't it ESRX that announced that the drug would be available to patients starting Jan 1, 2015 ? Usually its the drug manufacturer that announces when it will be available.
I hope someone looks into this, Can you imagine the culpability issues, anti-trust ?
No one can tell me that I am the only person that has thought of this .
If so make me your CEO, or at least your Head of Legal Affairs.
Selling 100 share lots of Gild on upticks to 105.80 to buy BX at anything below 32.60 - will see BX at 35 after the New Year heading into earnings, possibly a 1 dollar dividend for BX - BXMT increased their divvy by. 02 and BXMT accounts for only 5% of BX earnings - all good news for BX
The silver in this lining ?
There in no way in hell that this news is worth 30B - it will be back at 105 by earnings, GILD will take a shot across the bow soon -
it could be a tactical hit though - can you imagine a commercial spot by GILD depicting the possible side effects and the regiment you need to on if you used ABBVs drug ?
Doctors would need to fess up to their clients and that wouldn't bode well for the insurance companies
I say maybe they should make me their Head of Advertising
They would be in court faster than you can say SEC. The consensus number for 2015 is 9.88 - based on earnings prior to HPc where earnings were 3.30, Harvoni and Solvaldi would need to only account for 6.58, I think thats a more than sure thing, Share buyback will be the bonus, maybe moving this to maybe 10.50 2015 EPS, Was thinking, that voucher they bought - could it be that they are considering partnering with the company that has been able to cut the length of treatment by half ? Even at an 11 multiple, this thing should be just north of 115 right now
Maybe the SEC should take a quick look into the board members and management of Express Scripts and ABBV portfolios - wouldn't be surprised that someone here traded illegally
The 1st time someone dies from the side effects of ABBV Hep C drug there is going to be hell to pay. Express Scripts just opened themselves up to huge risk
I read an article somewhere where it was said that abbv's drug is only for 1 level of hep c while gild's is for all 4 and that their drug has possible severe side effects -
Note that he bought at 25 per share - its at 50+ right now
I think I will wait a bit on this one, just had an IPO and I can see the price coming down 30%
Several studies in Phase1/2 plus they have some legal issues with Novartis
Normal sell off into a long holiday weekend - just happy to see GILD close up.
Next wednesday it will be back up to 95 - we'll see 105 into earnings. Have held all shares through this blip.
Express Scripts has opened themselves up to extreme risk, if 1 patient dies because of not being able to get GILDs product and forced to use ABBVs product, game, set - match
Thomson Reuters/Verus downgrades GILEAD SCIENCES INC from HOLD to SELL.
BY Investars Analyst Actions - public
— 12:06 PM ET 12/08/2014
On December 8, 2014 Thomson Reuters/Verus downgraded GILEAD SCIENCES INC (GILD
) from HOLD to SELL.